![]() | |
Clinical data | |
---|---|
Other names | ABBV-552; ABBV552; SDI-118; SDI118 |
Routes of administration | Oral [1] |
Drug class | Synaptic vesicle glycoprotein 2A (SV2A) ligand [2] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C13H10ClF3N4O |
Molar mass | 330.70 g·mol−1 |
3D model (JSmol) | |
| |
|
Plosaracetam (INN ; developmental code names ABBV-552, SDI-118) is a synaptic vesicle glycoprotein 2A (SV2A) ligand which is under development for the treatment of Alzheimer's disease and other cognition disorders. [1] [3] [4] [2] In contrast to earlier SV2A ligands like levetiracetam and brivaracetam, polsaracetam does not have anticonvulsant activity and instead shows pro-cognitive effects. [2] The drug is being developed by UCB Biopharma and AbbVie. [1] [3] As of October 2024, it is in phase 2 clinical trials for Alzheimer's disease and phase 1 trials for cognition disorders. [1] [3]